01.26.26 -- Deploying A Vendor Life Cycle Oversight Model

RMAT qualification requires preliminary clinical evidence demonstrating the potential to address an unmet medical need. This designation grants benefits like intensive guidance and faster FDA review.

Demand for lentiviral vector manufacturing has increased. Explore how scalable, cost-effective, and high-quality LVV manufacturing can accelerate both ex vivo and emerging in vivo CAR-T therapies.

These tools and technology platforms are transforming drug development, enabling faster discovery, improved scalability, and greater precision across biologics, advanced therapies, and data-driven manufacturing.

Hear about how this company is overcoming purification challenges and advancing scalable, GMP-ready lentiviral vector manufacturing for gene and cell therapies.

Ensure the success of your tech transfer by addressing these key challenges and optimizing your processes for seamless scalability and compliance.

To develop a fruitful viral vector manufacturing process and a mutually beneficial relationship between sponsor and CDMO, learn to balance cost, quality, and timeline via transparent communication.

Viral vectors are the indispensable backbone of genetic medicine. Read about the fundamental trade-offs and manufacturing strategies for large-scale production of AAV and lentiviral delivery systems.

Discover why this area is poised to become a leading hub for cell and gene therapy, as highlighted by CCS and industry experts at the 6th Annual Supply Chain Summit.

Bispecific antibody quality control demands advanced analytics to detect mispaired species, assess structural integrity, and confirm potency, ensuring safety and efficacy across diverse therapeutic applications.

Use this guide to select the right CDMO partner for your pharmaceutical project to navigate the evolving drug development landscape and ensure successful outcomes.

See why collaboration and innovation are key to overcoming challenges and bringing life-changing cell and gene therapies to those in need.

Observe how to transform biopharma learning with a human-centered, AI-enhanced ecosystem that personalizes development, fosters engagement, and aligns training with real-world impact.